Latest On Mesoblast Limited (MESO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-26 06:19 EST | News | Mesoblast Limited (MESO) Q3 2023 Earnings Call Transcript | N/A |  |
| 2023-05-26 06:19 EST | News | Mesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18M | N/A | |
| 2023-05-04 20:51 EST | News | Mesoblast Has A Strong Upside Potential | N/A | |
| 2023-03-08 20:50 EST | News | Mesoblast stock surges ~10% on getting FDA review of graft versus host disease therapy | N/A | |
| 2023-03-02 11:37 EST | News | Mesoblast Limited. (MESO) Q2 2023 Earnings Call Transcript | N/A | |
About Mesoblast Limited (MESO):
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney disease read more...s, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.
General
- Name Mesoblast Limited
- Symbol MESO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 102
- Fiscal Year EndJune
- IPO Date2015-11-13
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.mesoblast.com
Valuation
- Forward PE 454.55
- Price/Sales (Trailing 12 Mt.) 62.46
- Price/Book (Most Recent Quarter) 2.28
- Enterprise Value Revenue 70.47
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.29
- Next Year EPS Estimate $0.17
- Operating Margin -682%
- Return on Assets -10%
- Return on Equity -19%
- Revenue 16.45 million
- Earnings Per Share -$0.91
- Revenue Per Share $0.15
- Gross Profit 6.85 million
- Quarterly Earnings Growth 1.6%
Highlights
- Market Capitalization 1.26 billion
- EBITDA -78815000
- Analyst Target Price $13.7
- Book Value Per Share $4.42
Share Statistics
- Shares Outstanding 129.62 million
- Shares Float 101.69 million
- % Held by Insiders <1%
- % Held by Institutions 2.87%
- Shares Short 1.88 million
- Shares Short Prior Month 2.82 million
- Short Ratio 4.29
- Short % of Shares Outstanding 2%
Technicals
- Beta 2.71
- 52 Week High $21.28
- 52 Week Low $3.12
- 50 Day Moving Average 9.64
- 200 Day Moving Average 12.23
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Mesoblast Limited (MESO) Dividend Calendar:
Mesoblast Limited (MESO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Mesoblast Limited (MESO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Mesoblast Limited (MESO) Chart:
Mesoblast Limited (MESO) News:
Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Mesoblast Limited (MESO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest MESO Trades:
Mesoblast Limited (MESO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-03 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-10-29 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-10-23 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-10-15 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-10-05 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-17 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-16 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-08 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-03 | 20-F (Annual and transition report of foreign private issuers [Sections 13 or 15(d)]) | |
| 2020-09-03 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-31 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-25 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-17 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-12 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-10 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-03 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-27 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-07-27 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-10 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-07 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |